SB's Factive not approved

Published: 3-Feb-2001


SmithKline Beecham has received a non-approval letter from the FDA for its antibiotic gemifloxacin mesylate (Factive). Although disappointed with the decision, the company says it still intends to pursue the product.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like